arthralgia incidence in trials is generally similar to placebo Rapid weight loss from GLP-1 treatment may alter biomechanical loading on joints, causing temporary adjustment-related discomfort Patients prescribed GLP-1 medications often have type 2 diabetes or obesity, conditions independently associated with increased osteoarthritis rates Seek medical advice for severe, worsening, or persistent joint pain, or if accompanied by swelling, redness, warmth, or systemic symptoms Report suspected medication side effects through the MHRA Yellow Card scheme to support ongoing safety monitoring Table of Contents Understanding GLP-1 Medications and Their Common Side Effects GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), most commonly cause gastrointestinal side effects such as nausea, vomiting, and diarrhoea
Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis
Microlymphatic aneurysms in patients with lipedema
Mszros M, Porkolb G, Kiss L, Pilbat AM, Kta Z, Kupihr Z, et al
We are excited to share insights into the groundbreaking world of semaglutide, also known as Ozempic, Wegovy & Mounjaro, a medication not only known for its effectiveness in managing type 2 diabetes but also for its remarkable impact on weight loss
Angiogenesis Promotes new blood vessel formation in damaged tissue by stimulating VEGF expression, creating vascular networks that deliver healing resources to the injury site